LOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

We used two cohorts for this study: (1) a Tempus cohort (TC) to investigate the genomic landscape and (2) a Stanford cohort (SC) where we include disease course and outcomes in addition to the genomic ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Bone is a common site for metastasis of solid cancers, but histological and molecular features of bone metastases are not well understood. In a new study published in Cell Genomics, researchers at ...

Symptoms of stage 3 RCC vary; some patients experience blood in the urine, flank pain, fatigue, weight loss, or a palpable abdominal mass, whereas others are diagnosed incidentally during imaging for ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

We conducted a retrospective nationwide study that included all patients diagnosed with RCC in Iceland between January 1, 1971 and December 31, 2005. The Icelandic Cancer Registry and centralized ...

Early PSA Response to Abiraterone Predicts Better Outcomes Use of the drug is associated with significantly longer progression-free survival compared with suninitib in treatment-naïve patients.

DENVER -- A majority of patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months when treated with cabozantinib (Cabometyx), ...